Current Role of Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non Small Cell Lung Cancer (NSCLC): Which Patients and Why

Last Modified: October 15, 2004

Share article


Conference Date: December 11, 2004
Conference Location: San Francisco, CA

Conference Date: January 8, 2005
Conference Location: Atlanta, GA

Conference Date: February 5, 2005
Conference Location: Philadelphia, PA

Conference Web Page URL: www.thecbce.com/futureprograms.asp

Topics Covered: This continuing medical education (CME) activity will compare the biology, clinical efficacy, and toxicity of small-molecule EGFR inhibitors in the treatment of NSCLC.

Conference Objectives:

Who Should Attend: This activity is designed primarily for medical oncologists and other physicians interested in the treatment of cancer.

Registration Information: To register, please visit our website at www.thecbce.com/futureprograms.asp or e-mail info@thecbce.com for more information.

Continuing Education: Yes


News
Tied to longer progression-free survival than standard chemo in patients with EGFR mutations

Jun 24, 2010 - Gefitinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor, is more effective than standard chemotherapy in extending life for patients with non-small-cell lung cancer who have epidermal growth factor receptor mutations, according to a study published in the June 24 issue of the New England Journal of Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More